These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 9084896)
1. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine. Ko HC; Lu RB; Shiah IS; Hwang CC Biol Psychiatry; 1997 Apr; 41(7):774-81. PubMed ID: 9084896 [TBL] [Abstract][Full Text] [Related]
2. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression? Castrogiovanni P; Blardi P; De Lalla A; Dell'Erba A; Auteri A Psychopharmacol Bull; 2003; 37(2):102-8. PubMed ID: 14566218 [TBL] [Abstract][Full Text] [Related]
3. Response to maprotiline treatment in depressive patients relationship to urinary MHPG excretion and plasma drug level. Gaertner HJ; Golfinopoulos G; Breyer-Pfaff U Pharmacopsychiatria; 1982 Sep; 15(5):170-4. PubMed ID: 7178231 [TBL] [Abstract][Full Text] [Related]
4. Urinary MHPG excretion and treatment with desipramine or amitriptyline: prediction of response, effect of treatment, and methodological hazards. Veith RC; Bielski RJ; Bloom V; Fawcett JA; Narasimhachari N; Friedel RO J Clin Psychopharmacol; 1983 Feb; 3(1):18-27. PubMed ID: 6833519 [TBL] [Abstract][Full Text] [Related]
5. [Plasma levels of MHPG, HVA and total 5-HIAA in depression. Preliminary study]. Raucoules D; Levy C; Azorin JM; Bruno M; Valli M Encephale; 1992; 18(6):611-6. PubMed ID: 1285270 [TBL] [Abstract][Full Text] [Related]
6. Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Yoshimura R; Nakamura J; Shinkai K; Ueda N Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):611-6. PubMed ID: 15276685 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients. Sandor P; Baker B; Irvine J; Dorian P; McKessok D; Mendlowitz S Depress Anxiety; 1998; 7(2):69-72. PubMed ID: 9614594 [TBL] [Abstract][Full Text] [Related]
8. Urinary 3-methoxy-4-hydroxyphenylglycol and the depression-type score as predictors of differential responses to antidepressants. Mooney JJ; Schatzberg AF; Cole JO; Samson JA; Waternaux C; Gerson B; Pappalardo KM; Schildkraut JJ J Clin Psychopharmacol; 1991 Dec; 11(6):339-43. PubMed ID: 1770151 [TBL] [Abstract][Full Text] [Related]
9. A quantitative magnetic resonance imaging study of cerebral and cerebellar gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. Pillay SS; Yurgelun-Todd DA; Bonello CM; Lafer B; Fava M; Renshaw PF Biol Psychiatry; 1997 Jul; 42(2):79-84. PubMed ID: 9209723 [TBL] [Abstract][Full Text] [Related]
10. A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients. Timmerman L; de Beurs P; Tan BK; Leijnse-Ybema H; Sanchez C; Høpfner Petersen HE; Cohen Stuart MH Int Clin Psychopharmacol; 1987 Jul; 2(3):239-53. PubMed ID: 2447151 [TBL] [Abstract][Full Text] [Related]
11. Plasma-free and sulfoconjugated MHPG in major depressive disorders: differences between responders to treatment and nonresponders. Mine K; Okada M; Mishima N; Fujiwara M; Nakagawa T Biol Psychiatry; 1993 Nov; 34(9):654-60. PubMed ID: 8292695 [TBL] [Abstract][Full Text] [Related]
12. Fluoxetine in the treatment of depression in Asian (Chinese and Indian) patients in Singapore. Tsoi WF; Tan CT; Kok LP Singapore Med J; 1995 Aug; 36(4):397-9. PubMed ID: 8919155 [TBL] [Abstract][Full Text] [Related]
13. MHPG as a predictor of antidepressant response to imipramine and maprotiline. Rosenbaum AH; Schatzberg AF; Maruta T; Orsulak PJ; Cole JO; Grab EL; Schildkraut JJ Am J Psychiatry; 1980 Sep; 137(9):1090-2. PubMed ID: 7425162 [TBL] [Abstract][Full Text] [Related]
14. Predictors of an acute antidepressant response to fluoxetine and sertraline. Flament MF; Lane RM; Zhu R; Ying Z Int Clin Psychopharmacol; 1999 Sep; 14(5):259-75. PubMed ID: 10529069 [TBL] [Abstract][Full Text] [Related]
15. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? Nierenberg AA; Pava JA; Clancy K; Rosenbaum JF; Fava M Biol Psychiatry; 1996 Oct; 40(8):691-6. PubMed ID: 8894060 [TBL] [Abstract][Full Text] [Related]
16. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement. Celada P; Pérez J; Alvarez E; Artigas F J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522 [TBL] [Abstract][Full Text] [Related]
17. Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. Dunner DL; Schmaling KB; Hendrickson H; Becker J; Lehman A; Bea C Depression; 1996; 4(1):34-41. PubMed ID: 9160652 [TBL] [Abstract][Full Text] [Related]
18. Problem-solving ability and comorbid personality disorders in depressed outpatients. Harley R; Petersen T; Scalia M; Papakostas GI; Farabaugh A; Fava M Depress Anxiety; 2006; 23(8):496-501. PubMed ID: 16845662 [TBL] [Abstract][Full Text] [Related]
19. Treatment of depression and anxiety in infertile women: cognitive behavioral therapy versus fluoxetine. Faramarzi M; Alipor A; Esmaelzadeh S; Kheirkhah F; Poladi K; Pash H J Affect Disord; 2008 May; 108(1-2):159-64. PubMed ID: 17936366 [TBL] [Abstract][Full Text] [Related]
20. Fluoxetine 40 mg vs maprotiline 75 mg in the treatment of out-patients with depressive disorders. Poelinger W; Haber H Int Clin Psychopharmacol; 1989 Jan; 4 Suppl 1():47-50. PubMed ID: 2644340 [No Abstract] [Full Text] [Related] [Next] [New Search]